Pulmonary arterial hypertension in systemic sclerosis: Can we predict responders for successful therapy?

Journal of Rheumatology

Volumn 36, Issue 4, 2009, Pages 665-666

  Sasahara, Arthur A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CARBON MONOXIDE; CYCLIC GMP; ENDOTHELIN; NITRIC OXIDE; PADGEM PROTEIN; PROSTACYCLIN; VASODILATOR AGENT;

CELL ACTIVITY; CONNECTIVE TISSUE DISEASE; ECHOCARDIOGRAPHY; EDITORIAL; ENDOTHELIUM CELL; HEMODYNAMICS; HUMAN; LUNG BLOOD FLOW; LUNG CIRCULATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; SYNDROME CREST; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; NOTE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 66149150582     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081322     Document Type: Editorial

References (9)

1. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43 Suppl:S5-S12.
3. Magliano M, Isenberg DA, Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum 2002;46:1997-2004.
4. Rubin LJ. Introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;176:7S-9S.
5. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-95.
6. Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue disease. J Rheumatol 2009;36:760-7.
7. Pietro DA, LaBresh KA, Shulman RM, Folland ED, Parisi AF, Sasahara AA. Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol. New Engl J Med 1984;310:1032-4.
8. Archer SL, Michelakis ED. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006;21:385-92.
9. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482-9.